The Chemours Company $CC Shares Bought by LPL Financial LLC

Key Points

• LPL Financial LLC significantly increased its stake in The Chemours Company by 77.8% in the first quarter, now holding approximately 122,317 shares valued at $1,655,000.
• Chemours reported a positive earnings per share (EPS) of $0.58 for the latest quarter, exceeding estimates, with revenues rising 5.0% year-over-year.
• The company has recently cut its dividend to $0.0875 per share, indicating a dividend payout ratio of -12.50% amid ongoing financial adjustments.

LPL Financial LLC increased its stake in The Chemours Company (NYSE:CC - Free Report) by 77.8% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 122,317 shares of the specialty chemicals company's stock after acquiring an additional 53,520 shares during the quarter. LPL Financial LLC owned approximately 0.08% of Chemours worth $1,655,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Private Management Group Inc. increased its holdings in Chemours by 22.1% in the 1st quarter. Private Management Group Inc. now owns 953,058 shares of the specialty chemicals company's stock worth $12,895,000 after acquiring an additional 172,392 shares in the last quarter. Readystate Asset Management LP purchased a new stake in Chemours in the 1st quarter worth $1,072,000. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in Chemours in the 1st quarter worth $174,000. Allianz Asset Management GmbH increased its holdings in Chemours by 51.5% in the 1st quarter. Allianz Asset Management GmbH now owns 669,603 shares of the specialty chemicals company's stock worth $9,060,000 after acquiring an additional 227,566 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Chemours by 46.0% in the 1st quarter. Victory Capital Management Inc. now owns 161,052 shares of the specialty chemicals company's stock worth $2,179,000 after acquiring an additional 50,741 shares in the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Insider Activity

In related news, insider Damian Gumpel bought 13,400 shares of the firm's stock in a transaction on Monday, June 2nd. The shares were bought at an average price of $9.22 per share, with a total value of $123,548.00. Following the completion of the transaction, the insider directly owned 123,879 shares of the company's stock, valued at $1,142,164.38. This represents a 12.13% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Denise Dignam bought 4,068 shares of the firm's stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $12.06 per share, for a total transaction of $49,060.08. Following the transaction, the chief executive officer directly owned 191,546 shares of the company's stock, valued at $2,310,044.76. The trade was a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders have bought 25,290 shares of company stock worth $250,437. Corporate insiders own 0.47% of the company's stock.

Chemours Trading Up 0.4%

Shares of CC stock traded up $0.06 on Wednesday, hitting $15.25. 1,785,100 shares of the stock traded hands, compared to its average volume of 4,517,311. The firm's 50-day moving average price is $13.16 and its two-hundred day moving average price is $12.89. The company has a debt-to-equity ratio of 17.16, a quick ratio of 0.83 and a current ratio of 1.68. The stock has a market capitalization of $2.28 billion, a PE ratio of -5.45 and a beta of 1.61. The Chemours Company has a twelve month low of $9.13 and a twelve month high of $22.38.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, August 5th. The specialty chemicals company reported $0.58 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.12. The firm had revenue of $1.62 billion for the quarter, compared to analysts' expectations of $1.57 billion. Chemours had a negative net margin of 7.19% and a positive return on equity of 35.14%. The company's revenue was up 5.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.38 EPS. Chemours has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts anticipate that The Chemours Company will post 2.03 EPS for the current year.

Chemours Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, September 12th. Stockholders of record on Friday, August 15th will be given a dividend of $0.0875 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $0.35 annualized dividend and a dividend yield of 2.3%. Chemours's payout ratio is presently -12.50%.

Analyst Ratings Changes

Several brokerages recently commented on CC. Royal Bank Of Canada boosted their price target on shares of Chemours from $14.00 to $15.00 and gave the stock an "outperform" rating in a report on Thursday, July 3rd. The Goldman Sachs Group dropped their target price on shares of Chemours from $21.00 to $14.00 and set a "neutral" rating for the company in a report on Wednesday, May 14th. Morgan Stanley dropped their target price on shares of Chemours from $22.00 to $15.00 and set an "equal weight" rating for the company in a report on Monday, May 12th. Barclays dropped their target price on shares of Chemours from $16.00 to $13.00 and set an "equal weight" rating for the company in a report on Wednesday, May 28th. Finally, Wall Street Zen lowered shares of Chemours from a "hold" rating to a "sell" rating in a report on Wednesday, May 21st. Five analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $17.38.

Chemours Company Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.